SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a
second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid
Tumors Group) and check up ORR difference by EGFR mutation, gender, smoking history, and type
of tumor.